阿柏西普治疗新生血管性年龄相关性黄斑变性的效果:观察性比较研究的系统综述与Meta分析
该系统综述与Meta分析纳入18项观察性比较研究,比较阿柏西普与其他抗血管内皮生长因子药物治疗初治新生血管性年龄相关性黄斑变性的真实世界效果。阿柏西普与雷珠单抗在2年治疗中效果相似,但在初始视力较低(logMAR>0.6或<55个字母)的患者中阿柏西普可能更有效。
要点
- 阿柏西普与雷珠单抗在2年治疗中效果相似,各时间点logMAR视力下降和中央视网膜厚度下降的差异均无统计学意义。
- 在初始视力较低(logMAR>0.6或<55个字母)的患者中,阿柏西普显著更有效(P=0.001)。
- 第一年治疗频率无显著差异,但按需治疗方案下阿柏西普所需注射次数少于雷珠单抗(均值-0.90;95%CI:-1.80至0.00)。
核心结论
- 在真实世界中,阿柏西普与雷珠单抗对初治新生血管性年龄相关性黄斑变性效果相当,对初始视力较低的患者可能更有效。
研究设计与样本
- 系统综述与Meta分析,纳入18项观察性比较研究(初筛1697项研究)。
- 研究对象为初治新生血管性年龄相关性黄斑变性患者,比较阿柏西普与其他抗血管内皮生长因子药物。
主要发现
- 阿柏西普与雷珠单抗组在3、6、12、24个月时logMAR视力下降的差异分别为0.00(95%CI:-0.03至0.02)、0.01(95%CI:-0.02至0.05)、-0.03(95%CI:-0.07至0.01)、-0.06(95%CI:-0.30至0.17)。
- 阿柏西普与雷珠单抗组在3、6、12、24个月时中央视网膜厚度下降的差异分别为3.25 μm(95%CI:-15.03至21.53)、7.89 μm(95%CI:-31.91至47.69)、2.89 μm(95%CI:-18.33至24.11)、-2.42 μm(95%CI:-77.87至73.03)。
- 在初始视力较低(logMAR>0.6或<55个字母)的患者中,阿柏西普显著更有效(P=0.001)。
- 第一年治疗频率在阿柏西普与雷珠单抗间无显著差异,但按需治疗方案下阿柏西普所需注射次数少于雷珠单抗(均值-0.90;95%CI:-1.80至0.00)。
关键数值与推荐
- 最常见的阿柏西普治疗方案为每月注射三次后按需治疗。
- 初始视力较低定义为logMAR>0.6或<55个字母。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSES: To compare the effects of aflibercept and other anti-vascular endothelial growth factor (anti-VEGF) medications on both functional and anatomical outcomes for treatment-naïve neovascular age-related macular degeneration (nAMD) in the real world. METHODS: A systematic review and meta-analysis of observational comparative studies. RESULTS: A total of 18 studies remained after literature selection and quality assessment of 1697 studies. The most common aflibercept treatment regimen was three monthly injections followed by pro re nata (PRN). Aflibercept and ranibizumab had similar effects in 2-year treatment. At 3, 6, 12, and 24 months, the differences in the logarithm of minimum angle of resolution (logMAR) decrease in aflibercept and ranibizumab groups were 0.00 (95% confidence interval [CI]: -0.03 to 0.02); 0.01 (95% CI: -0.02 to 0.05); -0.03 (95% CI: -0.07 to 0.01); and -0.06 (95% CI: -0.30 to 0.17), respectively; the differences in decrease of central retinal thickness (CRT) were 3.25 μm (95% CI: -15.03 to 21.53); 7.89 μm (95% CI: -31.91 to 47.69); 2.89 μm (95% CI: -18.33 to 24.11); and -2.42 μm (95% CI: -77.87 to 73.03), respectively. However, aflibercept was significantly more effective in patients with initial reduced visual acuity (logMAR >0.6 or <55 letters; P = 0.001). In the first year, treatment frequency was not significantly different for aflibercept and ranibizumab, but aflibercept required fewer injections than ranibizumab with PRN regimen (mean -0.90; 95% CI: -1.80 to 0.00). CONCLUSIONS: Aflibercept has comparable effects with ranibizumab for treatment-naïve nAMD in the real world, and may be more effective for patients with initial lower visual acuity.
引用
- Zhang Y, Chioreso C, Schweizer ML, et al. Effects of Aflibercept for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis of Observational Comparative Studies. Invest Ophthalmol Vis Sci. 2017. PMID: 29094167. doi:10.1167/iovs.17-22471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。